

**DUR Committee Agenda
November 10, 2015**

**Office of MaineCare Services, Department of Health and Human Services
Augusta Armory
Augusta, Maine
6:00 to 8:00 pm**

Call to Order: 6:00 pm

Public Comments - Open Session

Old Business:

Approval of Minutes (5 mins)

MaineCare Update (5 mins)

Closed Session:

Financial Discussion (20 mins)

New Business:

- A) Updated Hepatitis C PA form (10 mins)
- B) PSCK 9 Inhibitors- Criteria and PA form (10 mins)
- C) RetroDUR- Analysis of appropriate Testosterone use
- D) New Drug Review (45 mins)
 - Aristada Inj
 - Odomzo
 - Synjardy
 - Zarxio
 - Zecuity Patch
- E) FDA Safety Alerts (20 mins)

Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm461876.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Safe medicine disposal options

<http://www.fda.gov/Drugs/NewsEvents/ucm464197.htm>

Acetaminophen Tablets by Medline Industries: Recall - Mislabeling with Incorrect Strength

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm467076.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie

http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA requires drug interaction studies with potassium-lowering drug Kayexalate (sodium polystyrene sulfonate)

http://www.fda.gov/Drugs/DrugSafety/ucm468035.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA review found no increased cardiovascular risks with Parkinson's disease drug entacapone

http://www.fda.gov/Drugs/DrugSafety/ucm468803.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA cautions about dose confusion and medication error with antibacterial drug Avycaz (ceftazidime and avibactam)

http://www.fda.gov/Drugs/DrugSafety/ucm463248.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

FDA Drug Safety Communication: FDA evaluating the risks of using the pain medicine tramadol in children aged 17 and younger

http://www.fda.gov/Drugs/DrugSafety/ucm462991.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Auvi-Q (epinephrine injection, USP): Recall - Potential Inaccurate Dosage Delivery

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm470010.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Next meeting: January 12th 2016 6-8pm

Adjournment: 8:00 pm